Clearside Biomedical (CLSD) has issued an announcement. Clearside Biomedical, Inc. has appointed Anthony S. Gibney, a seasoned executive with a rich history in biotech and investment banking, as a new
Clearside Biomedical (CLSD) has issued an announcement. Clearside Biomedical, Inc. has appointed Anthony S. Gibney, a seasoned executive with a rich history in biotech and investment banking, as a new
Clearside Biomedical announced that Anthony Gibney has been appointed to the Company’s Board of Directors, effective April 15, 2024. Most recently, Gibney served as the Executive Vice President, Chief Business
גיבני, שעבד לאחרונה כבכיר העסקים והאסטרטגיה ב-Iveric Bio, יתחיל בתפקידו החדש ב-15 באפריל 2024.
Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abivax SA Sponsored ADR (ABVX – Research Report), RxSight (RXST – Research Report) and Clearside Biomedical (CLSD – Research Report).
Abivax SA Sponsored ADR (ABVX)
In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Abivax SA Sponsored ADR, with a price target of $16.00. The company’s shares closed last Wednesday at $15.39.
According to TipRanks.com, Purohit is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Abivax SA Sponsored ADR is a Moderate Buy with an average price target of $24.00.
See today’s best-performing stocks on TipRanks >>
RxSight (RXST)
In a report released today, David Saxon from Needham maintained a Buy rating on RxSight, with a price target of $64.00. The company’s shares closed last Wednesday at $52.72, close to its 52-week high of $58.21.
According to TipRanks.com, Saxon is a 4-star analyst with an average return of
RxSight has an analyst consensus of Strong Buy, with a price target consensus of $62.57.
Clearside Biomedical (CLSD)
Needham analyst Serge Belanger maintained a Buy rating on Clearside Biomedical today and set a price target of $4.00. The company’s shares closed last Wednesday at $1.24.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of
Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $4.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ABVX: